

## Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue

The English pressrelease that was sent 6 February 2026 at 17.50 CET, which is a translation of the Swedish press release sent at the same time included an additional sentence by mistake. The following pressrelease is the correct version.

**NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.**

LIDDS AB (publ) ("LIDDS" or the "Company") today announces the preliminary outcome of the rights issue with preferential rights for the shareholders (the "Rights Issue"), which subscription period ended today. The subscription breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights Issue, were subscribed for with or without the exercise of subscription rights. The Rights Issue was secured to approximately 95.7 percent through issue guarantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.

"I would like to thank all existing shareholders who have participated in the rights issue for your continued support and extend a warm welcome to new shareholders. The rights issue provides a significant reinforcement to the Company's continued development of Nanodotax and Nanoimod and enables intensified work with the out-licensing of the Phase III project Liproca® Depot", says Anders Månsson, CEO of LIDDS.

The subscription period in the Rights Issue ended today the 6 February 2023 and a preliminary breakdown shows that 24,967,268 shares, corresponding to 35.0 MSEK or approximately 71.9 percent of the Rights issue, were subscribed for with or without the exercise of subscription rights. The Rights Issue was secured to approximately 95.7 percent through issue guarantees and the Company will therefore obtain approximately 46.5 MSEK before issue costs.

The final outcome of the Rights Issue is expected to be announced on Wednesday 8 February 2023. Allocation of shares that were subscribed for without the exercise of subscription rights will be done according to the principles described in the prospectus that was prepared in connection with the Rights Issue and was published on 17 January 2023. Those who will be allocated shares without the support of subscription rights will be notified after the allocation meeting held by the Board of Directors on 8 February 2023 through contract note. Nominee shareholders will receive notification of allotment in accordance with the respective nominee's routines. Allocated shares should be paid according to the instructions on the contract note.

## **Advisors**

Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.

## **For additional information, please contact**

---

Anders Månsson, CEO

Phone: +46 (0)70 860 47 38

E-mail: [anders.mansson@liddspharma.com](mailto:anders.mansson@liddspharma.com)

Jenni Björnulfson, CFO

Phone: +46 (0)70 855 38 05

E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

## **LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

## Important information

---

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in LIDDS. No action has been taken and no action will be taken to permit an offer to the public in any jurisdictions other than Sweden.

This press release may not be published or distributed, directly or indirectly, in or to Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, the United States or any other jurisdiction where such action in whole or in part is subject to legal restrictions, or would require additional prospectus, registration or other measures than what follows from Swedish law. The information in this press release may also not be forwarded or reproduced in a way that is contrary to such restrictions or would entail such requirements. Actions contrary to this instruction may constitute a violation of applicable securities legislation. Neither subscription rights, paid and subscribed shares nor new shares subscribed for in the offering have been registered or will be registered under the United States Securities Act of 1933 as currently amended ("Securities Act") and may not be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or to the United States, except pursuant to an applicable exemption from the registration requirements of the Securities Act. The offer is also not directed at persons domiciled in Australia, Canada, Hong Kong, Japan, New Zealand, Switzerland, Singapore, South Africa or in any other jurisdiction where participation would require additional prospectus, registration or other measures than those that follow from Swedish law.

## Forward-looking statements

This press release contains certain forward-looking statements that reflect LIDDS' current views and expectations regarding future events and financial and operational developments, including statements regarding the offering and statements regarding guidance, planning, prospects and strategies. Words such as "intended," "predicted," "expected," "planned," "estimated," "may," and other expressions that imply indications or predictions of future developments or trends and are not based on historical facts constitute forward-looking statements information. Although LIDDS believes that these statements are based on reasonable assumptions and expectations, LIDDS cannot guarantee that such forward-looking statements will be realized. Because these forward-looking statements involve both known and unknown risks and uncertainties, actual outcomes may differ materially from those expressed in forward-looking information. Forward-looking statements in the press release speak only as of the date of the press release and are subject to change without notice. The company makes no promises to publish updates or revisions to forward-looking statements as a result of new information, future events or the like beyond what is required by applicable laws or stock market regulation.

## Attachments

---

**Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue**